The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for patients with severe asthma with an eosinophilic phenotype, GSK announced. The ...
Robust real-world data on the effectiveness of biologic therapies in children with severe asthma remain limited, particularly ...
Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two doses annually. Phase 3 trials demonstrated significant reductions in asthma ...
To inform clinicians on the best biologic agent for different populations of adults with severe asthma, 12 experts collaborated on a new clinical practice guideline published in CHEST, according to a ...
More than 75% of adults in a virtual asthma self-management education program had improved asthma control afterward, according to data presented at the American Academy of Allergy, Asthma & Immunology ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results